Biomarin Pharmaceutical Inc (NASDAQ:BMRN)
| 88.50 Delayed Data As of Sep 29 |  -0.75 / -0.84%Today’s Change | 80.53 Today|||52-Week Range 117.77 | -14.48% Year-to-Date |
Latest BMRN News | Press Releases
| 4 Awe-Inspiring Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip Sep 23 / MotleyFool.com - Paid Partner Content | CHMP Endorses BioMarin's (BMRN) Voxzogo for Use in Infants Sep 18 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 89.25 |
| Today’s open | 89.84 |
| Day’s range | 88.34 - 89.94 |
| Volume | 43,728 |
| Average volume (3 months) | 1,250,988 |
| Market cap | $16.7B |
Data as of 4:00pm ET, 09/29/2023
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +49.68% |
| Earnings growth (next 5 years) | +1.75% |
| Revenue growth (last year) | +10.91% |
| P/E ratio | 170.2 |
| Price/Sales | 9.55 |
| Price/Book | 3.58 |
Competitors
| ---- | ||
| EXASExact Sciences Corp | -0.98 | -1.42% |
| ILMNIllumina Inc | +4.92 | +3.72% |
| NBIXNeurocrine Bioscienc... | -2.69 | -2.34% |
Data as of 4:00pm ET, 09/29/2023
Financials
| Next reporting date | October 25, 2023 |
| EPS forecast (this quarter) | $0.23 |
| Annual revenue (last year) | $2.0B |
| Annual profit (last year) | $141.6M |
| Net profit margin | 6.91% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Rafael, California |
Forecasts
